|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||30.11 - 30.21|
|52 Week Range||26.11 - 30.29|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.70%|
First Trust Advisors L.P. announces the declaration of distributions for 116 exchange-traded funds advised by FTA.
In 1H17, Novartis’s (NVS) Promacta/Revolade reported revenues of around $385 million, which reflected ~33% growth on a year-over-year (or YoY) basis.
Three analysts were analyzing Novartis in September 2017. One analyst recommended a “strong buy,” while the other two recommended a “hold.”
FMC Technologies and Technip merged to become TechnipFMC (FTI) in 2017, an international provider of subsea, onshore, offshore, and surface projects. The synergy aims to combat the challenges of low oil…...
GlaxoSmithKline (GSK) reported revenues of 7.32 billion pounds in 2Q17—12% growth compared to revenues of 6.53 billion pounds in 2Q16.
Novartis (NVS) reported flat revenues of $12.24 billion on a constant-currency basis for 2Q17. This included a 2% decline due to foreign exchange.
Bristol-Myers Squibb (BMY) met Wall Street analysts’ estimate for EPS at $0.74. It also surpassed the estimates for revenues.
Sanofi’s (SNY) generic business contributed ~5.1% of its total revenue in 2Q17. The business reported revenue of 442 million euros in 2Q17, an 8% decrease from 2Q16. Revenue fell due…
Sanofi (SNY), one of the world's largest pharmaceutical companies, reported operational growth of 5.5% to reach revenue of 8.7 billion euros in 2Q17.
Intel (INTC) released its 2Q17 results on July 27, 2017. The company’s revenue and EPS for the first half of 2017 rose 8.5% and 72.0%, respectively.
Analysts expect to see a growth of ~11.4% in GlaxoSmithKline’s (GSK) 2Q17 revenues, which are expected to total nearly 7.3 billion British pounds.
First Trust, one of the largest issuers of smart beta exchange-traded funds, last week introduced six ETFs based on the Nasdaq Riskalyze indexes. Those benchmarks “are designed to provide diversified, ...
First Trust Advisors L.P. announces the declaration of distributions for 108 exchange-traded funds advised by FTA.
The expectation of a dovish stance on future rate hikes in the June Fed meeting has given a boost to demand for dividend-paying stocks.
Novartis reported EPS of $1.13 on revenues of $11.54 billion for 1Q17, which represents 2% YoY operational growth in revenues.
Novartis’s (NVS) Innovative Medicines segment includes products for therapeutic areas such as oncology, cardiometabolic, immunology, and dermatology.